ProCE Banner Activity

CME

Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Multimedia
In this on-demand webcast, Asim V. Farooq, MD; Joann Kang, MD; and Paul G. Richardson, MD, review the pathophysiology of ocular toxicities caused by antibody–drug conjugates used to treat cancer and provide guidelines on monitoring and managing these toxicities.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: January 05, 2022

Expiration: January 04, 2023

No longer available for credit.

Share

Faculty

Asim V. Farooq

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Joann Kang

Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Paul G. Richardson

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Target Audience

This educational program is intended for ophthalmologists, optometrists, medical oncologists, and other healthcare professionals who provide care for patients receiving antibody–drug conjugates for the treatment of cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the available data and expert recommendations to optimally monitor for ocular toxicity in patients with cancer who are receiving antibody–drug conjugates
  • Plan appropriate therapeutic interventions with treating hematologists and oncologists in patients experiencing ocular toxicities from antibody–drug conjugate therapy to maximize clinical outcomes from anticancer therapy and mitigate worsening keratopathy
  • Describe the pathophysiology of corneal toxicity associated with antibody–drug conjugates

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Asim V. Farooq, MD, has disclosed that he has received consulting fees from Five Prime Therapeutics/Amgen and GlaxoSmithKline.

Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Joann Kang, MD, has no relevant conflicts of interest to report.

Paul G. Richardson, MD

Associate Professor of Medicine
Harvard Medical School
Clinical Director
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides, and Takeda and has served on advisory boards for AstraZeneca, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, and Takeda.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 05, 2022, through January 04, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this program is to improve the knowledge and competence of learners in the mitigation and management of ocular toxicity for patients with cancer who are receiving antibody–drug conjugates.